Veliflapon

DB16346InvestigationalSmall molecule

Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

Mechanism: Pharmacologically active on Arachidonate 5-lipoxygenase-activating protein
Curator reviewed
Formula / weight: C₂₃H₂₃NO₃ · 361.441 g/mol (avg)
Code names: BAY-X-005 · BAY-X-1005 · DG-031

Resolves to

Compound

UNIIJXH6X663L0CAS128253-31-6ChEMBLCHEMBL88712

Structure

InChIKeyZEYYDOLCHFETHQ-JOCHJYFZSA-NSMILESOC(=O)[C@H](C1CCCC1)C1=CC=C(OCC2=NC3=C(C=CC=C3)C=C2)C=C1

Targets

P20292ALOX5AP

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Veliflapon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account